SOLID TUMOR, ADULT

This early-stage study tests a new oral drug, TYRA-430, in people with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. About 100 adults will take part, and the st…

This study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …

This early-phase trial tests ATTR-01, a modified cold virus designed to infect and destroy cancer cells while delivering an immune-boosting therapy. It is for adults with certain solid tumors who have not responded to standard treatments. The study aims to find the safest and mos…

This early-phase trial tests an experimental drug called IMA402 in about 145 adults with solid tumors that have returned or not responded to standard treatments. The drug is designed to help the immune system find and attack cancer cells that carry a protein called PRAME. The mai…

This study tests a new experimental drug, DB-1419, in adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 360 participants wi…

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to see if the combination is safe and tolerable. About 33 participants will be enrolled to a…

This study is testing whether a combination of two experimental drugs, AK119 and AK112, can safely shrink or control advanced solid tumors that have not responded to standard treatments. About 87 adults aged 18 to 75 with various advanced cancers will receive the drug combination…

This study tests a new treatment called GT201 for people with advanced solid tumors. GT201 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and then given back to fight the cancer. The trial aims to find a safe dose and see if it can shri…

This study tests a new drug called ACE-86225106 in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that are hard to treat or no longer respond to standard therapy. The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 298 par…

This study tests a new drug, CX-2051, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety and see if it can shrink tumors. About 160 participants will receive the drug alone or with another medicine called be…

This study tests an inhaled treatment called KB707 for people with advanced solid tumors that have spread to the lungs. KB707 is a modified virus designed to trigger the immune system to attack cancer cells. The trial involves 250 adults who have not responded to standard treatme…

This study tests whether adding a drug called ATRA (related to vitamin A) to targeted radiation therapy can prevent a drop in infection-fighting white blood cells (lymphocytes) in adults with solid tumors that have spread to a few spots. About 58 participants will receive radiati…

This study is testing whether combining an immunotherapy drug (atezolizumab), an immune-boosting agent (BDB001), and targeted radiation can help control advanced solid tumors. It includes people with pancreatic cancer, lung cancer, melanoma, bladder cancer, triple-negative breast…

This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…

This study tests a new drug called CRB-701 in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called nectin-4 found on cancer cells. The goal is to find a safe and effective dose and see which cancers it may help. Particip…

This early-stage study tests the safety of an experimental drug, OK-1 (SHetA2), in adults with advanced or recurrent solid tumors that have not responded to other treatments. About 50 participants will receive the drug to find the best dose and see how it affects the cancer. The …

This study tests an experimental drug called LNS8801, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink t…

This early-phase study tests a new drug called INV-1120, either by itself or combined with pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and check for side effects. About 7…

This early study tests a new drug called CX-801, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 121 people will take part.

This study tests an experimental drug, HMPL-453, in adults with advanced bile duct cancer that has a specific change in the FGFR2 gene. The drug is taken as a pill for 14 days, then a week off. The main goal is to see if it shrinks tumors. About 235 people will join.

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors (like colorectal, lung, or pancreatic cancer) that have lost a specific marker on their cells. The treatment uses the patient's own immune cells, modified to target cancer cells while protecti…

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The mai…

This early-stage trial tests whether customizing radiotherapy based on how a person's tumor responds can improve safety and effectiveness. It involves 45 adults with certain lung cancers, brain metastases, or solid tumors. The goal is to see if adapting radiation doses can better…

This study tests a new treatment for adults with solid tumors that have come back or not responded to standard therapies. The treatment uses a patient's own immune cells that are genetically modified to recognize and attack cancer cells. Some participants will also receive the dr…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have certain genetic changes. The study aims to find safe doses of KQB198 alone or with other cancer drugs, and to see if it can shrink tumors. About 100 participants will take the dru…

This study tests a drug called patritumab deruxtecan in adults with advanced solid tumors that have a rare genetic change called an NRG1 fusion. The goal is to see if the drug can shrink tumors or stop them from growing. About 30 people will take part, and the study is currently …

This early-phase study tests an oral drug called HQP1351 in about 100 people with advanced GIST (a type of stomach tumor) or other solid tumors. The main goal is to find a safe dose and see how the body processes the drug. Researchers will also watch for any signs that the drug s…

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study tests whether the drug nivolumab can be safely given after a half-matched bone marrow transplant to help prevent sarcomas from coming back. It includes children and young adults (ages 1 to 50) who have recently had this transplant and are at high risk of relapse. Resea…

This early-stage trial tests a new antibody (BI-1206) combined with an existing immunotherapy (pembrolizumab) in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can help control the disease. …

This early-phase study tests a new drug called ADU-1805, alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. About 130 p…

This early-stage study tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 230 participants w…

This early study tests a personalized treatment called GT307, made from a patient's own tumor-fighting immune cells. It is for adults with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the best dose, while also lo…

This study tests two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors, especially in cancers with a RAS mutation. About 83 adults wil…

This study tests whether a drug called TSR-042, followed by standard chemotherapy and radiation, can shrink or eliminate advanced solid tumors that have a specific genetic flaw (mismatch repair deficiency). About 200 adults with locally advanced tumors that haven't spread will re…

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

This early-phase study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose with manageable side effects. The drugs targe…

This study tests an experimental drug called VT3989, taken daily by mouth, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety and side effects, and to …

This early-stage trial tests an experimental pill called TRE-515 in people with advanced solid tumors that have not responded to standard treatments. The drug works by blocking a key enzyme cancer cells need to make DNA, potentially slowing tumor growth. The main goals are to fin…

This early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…

This study tests a combination of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) to see if they are safe and can control advanced solid tumors or relapsed prostate cancer. About 76 adults with these cancers will take the drugs and be monitor…

This is an early-stage study testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack can…

This study tests a new radioactive tracer called 64Cu-GRIP B that lights up immune activity in PET scans. It aims to see if the tracer is safe and can help detect which advanced cancers (like prostate, kidney, or bladder) are more likely to respond to immunotherapy. About 91 adul…

This study aims to adapt a counseling approach called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers will work with 190 participants to see if the culturally tailored program improves spiritual well-being and eases anxiety and depressio…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, have trouble sleeping, or are very tired. The program is delivered through telehealth (video or phone calls). Researchers want to see if patients …

This study adapts a counseling method called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers want to see if this culturally tailored program can improve quality of life and spiritual well-being. About 285 adults with stage III or IV soli…

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses and patients talk about the patient's health-related values as part of routine cancer care. The goal is to make care more personal and supportive. About 234 adult…

This study is creating a detailed database of 651 adults with solid tumors who are starting immunotherapy. Researchers will track their health over 5 years to see how well these treatments work in everyday medical practice. The goal is to learn more about outcomes like survival a…

This study uses a special microscope called intravital microscopy (IVM) to watch blood vessels inside solid tumors in real time during surgery. Researchers want to understand how these vessels work, which could help decide if a patient's tumor is likely to respond to certain trea…

This observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…

This study collects blood samples from 1,500 adults, including cancer patients and healthy volunteers, to help create a device that can grow and test immune cells outside the body. Researchers will look at specific immune cells and see how well they can attack tumor cells in the …